A STAT+ report says GOP lawmakers are pushing the Trump administration to ensure clinical trials are more diverse, arguing that the issue is about enrolling trial populations that better reflect the patients who will receive the therapies—not a DEI policy in the hiring or communications sense. The story traces how clinical trial diversity became caught in broader DEI rollbacks after Trump took office, including efforts by HHS to remove references to DEI from agency websites. Supporters of trial diversity counter that the clinical rationale is fundamental: trial results are most interpretable when study enrollment aligns with real-world disease demographics. The report does not cite specific legislative text or final regulatory actions, but it frames a near-term policy fight over how the FDA and HHS interpret and implement trial enrollment expectations.